Abstract Library

#4667 Clinical outcomes in patients with typical (TC) and atypical bronchial carcinoids (AC): A 15-year retrospective study from an ENETS Center of Excellence

Introduction: Bronchial neuroendocrine neoplasms (NENs) can be subdivided into TCs, ACs and neuroendocrine carcinomas (NECs). Although a few studies have explored treatment approaches and oncological outcomes, most focus on surgical cohorts, small sample sizes, or mixed groups including TC, AC, and NECs. Real-life cohort data are lacking.

Conference:

Presenting Author: Clement D

Authors: Correia J, Sarker D, Dolly S, Frydman A, Srirajaskanthan R,

Keywords: bronchial carcinoid, treatment pattern, recurrence-free survival, overall survival,

#4666 Merkel cell neuroendocrine carcinoma of the skin: High response rates to short course palliative radiotherapy – Typical clinical scenarios

Introduction: Merkel cell carcinomas (MCC) are a rare, aggressive skin neuroendocrine carcinomas, with peak incidence in the elderly. MCC often presents as a firm, red/purple painless nodule with a short history of increasing size. Surgery is considered the 1st line treatment but elderly patients, in particular, have comorbidities which may preclude radical surgery requiring reconstruction. In advanced MCC, immunotherapy (IO) is 1st line systemic treatment. Chemotherapy is used 2nd line or if contraindications for IO but can be challenging in an elderly population. There may be an emerging role for PRRT due to the presence of somatostatin receptors on MCC. Radiotherapy (RT) can be used for non-surgical candidates, or those with unresectable or metastatic disease. Adjuvant post-operative irradiation (PORT) may provide additional benefit in risk reduction and improves local control.

Conference:

Presenting Author:

Authors: Saunders E, Sizer B, Collins J, Skelly R, Srinivasan G,

Keywords: Merkel cell, skin, radiotherapy,

#4605 Primary mammary neuroendocrine tumour: A case report and literature review

Introduction: Primary neuroendocrine carcinomas of the breast are rare, accounting for only 2 to 5% of all breast cancers. These tumours have recently been included in the latest WHO classification of breast tumours. The diagnosis can be challenging due to its uncommon presentation and overlap with other breast pathologies.

Conference:

Presenting Author:

Authors: Boudersa A, Kouadri N,

Keywords: primary neuroendocrine, breast cancer,

#4557 miR-1290 and miR-320c regulate cell proliferation and predict patient prognosis in neuroendocrine carcinomas

Introduction: The biology of neuroendocrine carcinomas (NECs) remains largely unknown, limiting the use of biomarkers for patient stratification and therapy response prediction in clinical practice.

Conference:

Presenting Author: Liverani C

Authors: Liverani C, Sgolacchia F, Bongiovanni A, Calabrese C, Vanni S,

Keywords: biomarker, miRNAs, neuroendocrine carcinoma,

#4457 Primary mixed hepatocellular carcinoma-neuroendocrine carcinoma: A case report

Introduction: Mixed epithelial neoplasms (MiNENs) are characterised by the coexistence of neuroendocrine and non-neuroendocrine components within a single tumour, each discernible histologically and immunohistochemically, with a minimum tumour proportion of 30%. Primary hepatic MiNENs are exceedingly rare entities.

Conference:

Presenting Author: Tang Y

Authors: Wang Y, Wang R, Yi X, Guo M, Tang Y,

Keywords: pancreatic neuroendocrine tumour, functional, parathyroid hormone related peptide,